Cargando…

Analysis of Myocarditis Among 252 Million mRNA-1273 Recipients Worldwide

BACKGROUND: Growing evidence indicates a causal relationship between SARS-CoV-2 infection and myocarditis. Post-authorization safety data have also identified myocarditis as a rare safety event following mRNA COVID-19 vaccination, particularly among adolescent and young-adult males after dose 2. We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Straus, Walter, Urdaneta, Veronica, Esposito, Daina B, Mansi, James A, Sanz Rodriguez, Cesar, Burton, Paul, Vega, José M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384217/ https://www.ncbi.nlm.nih.gov/pubmed/35666513 http://dx.doi.org/10.1093/cid/ciac446

Ejemplares similares

2391. Evaluation and Adjudication of Case Reports of Myocarditis After mRNA-1273 Vaccination
por: Urdaneta, Veronica, et al.
Publicado: (2023)

2336. General Safety Profile of mRNA-1273 (Moderna COVID-19 Vaccine) in the Elderly Population
por: Anteyi, Kate, et al.
Publicado: (2023)

Relative Effectiveness of BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines and Homologous Boosting in Preventing COVID-19 in Adults in the US
por: Hung Nguyen, Van, et al.
Publicado: (2023)

mRNA-1273: Myocarditis: case report
Publicado: (2021)

mrna-1273: Acute myocarditis: case report
Publicado: (2021)

mrna-1273/tozinameran: Myocarditis: 8 case reports
Publicado: (2021)

Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial
por: El Sahly, Hana M, et al.
Publicado: (2022)

mRNA-1273/tozinameran: Myocarditis: 6 case reports
Publicado: (2021)

mRNA-1273/tozinameran: Myocarditis: 3 case reports
Publicado: (2021)

mRNA-1273/tozinameran: Myocarditis: 4 case reports
Publicado: (2022)

Myocarditis following COVID‐19 mRNA (mRNA‐1273) vaccination
por: Chellapandian, Suresh Babu, et al.
Publicado: (2022)

2357. Descriptive Analyses of mRNA-1273 (Moderna COVID-19 vaccine) Spontaneous Reports by Geographic Regions
por: Emile-Backer, Magalie, et al.
Publicado: (2023)

mRNA-1273/tozinameran: Acute myocarditis: 5 case reports
Publicado: (2022)

Acute Myocarditis Following Vaccination With the First Dose of the mRNA-1273 Vaccine
por: Olagunju, Abdulbaril, et al.
Publicado: (2022)

Immunogenicity of an Additional mRNA-1273 SARS-CoV-2 Vaccination in People With HIV With Hyporesponse After Primary Vaccination
por: Jongkees, Marlou J, et al.
Publicado: (2022)

Acute Myocarditis Following mRNA-1273 SARS-CoV-2 Vaccination
por: Williams, Curtis B., et al.
Publicado: (2021)

Acute myocarditis after the third dose of COVID‐19 mRNA‐1273 vaccine
por: Yamada, Takayuki
Publicado: (2023)

Myocarditis Following Coronavirus Disease 2019 mRNA Vaccine: A Case Series and Incidence Rate Determination
por: Perez, Yalile, et al.
Publicado: (2021)

8 million cases worldwide
por: Vaughan, Adam
Publicado: (2020)

A 17-year-old male with acute myocarditis following mRNA-1273 vaccination in Japan
por: Iwamuro, Ayumi, et al.
Publicado: (2022)

Acute Myocarditis in a Patient Following mRNA-1273 SARS-CoV-2 Vaccination
por: Kawakami, Toshinaru, et al.
Publicado: (2022)

Myocarditis After the Third Dose of mRNA-1273 Coronavirus Disease 2019 (COVID-19) Vaccine
por: Kawahara, Hiroshi, et al.
Publicado: (2022)

Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients
por: Hall, Victoria G., et al.
Publicado: (2021)

Effectiveness of Messenger RNA-1273 Vaccine Booster Against Coronavirus Disease 2019 in Immunocompetent Adults
por: Florea, Ana, et al.
Publicado: (2022)

Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination
por: Goddard, Kristin, et al.
Publicado: (2022)

Severe Myocarditis in a Female Following mRNA-1273 Vaccine: A Case Report and Review of the Literature
por: AL-Qudah, Bara M, et al.
Publicado: (2022)

No Immunological Interference or Safety Concerns When Adjuvanted Recombinant Zoster Vaccine Is Coadministered With a Coronavirus Disease 2019 mRNA-1273 Booster Vaccine in Adults Aged 50 Years and Older: A Randomized Trial
por: Naficy, Abdi, et al.
Publicado: (2023)

Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines
por: Naranbhai, Vivek, et al.
Publicado: (2021)

Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial
por: Speich, Benjamin, et al.
Publicado: (2022)

2359. Relative effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines in adults at higher risk for severe COVID-19 outcomes
por: Nguyen, Van Hung, et al.
Publicado: (2023)

Case report: acute myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine
por: Tailor, Prashant D, et al.
Publicado: (2021)

Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States
por: Mues, Katherine E., et al.
Publicado: (2022)

Myocarditis after BNT162b2 and mRNA-1273 COVID-19 vaccination: A report of 7 cases
por: Ahmed, Sirwan Khalid
Publicado: (2022)

Simultaneous Occurrence of Immune-Mediated Thrombocytopenia and Myocarditis After mRNA-1273 COVID-19 Vaccination: A Case Report
por: Bae, Dae-Hwan, et al.
Publicado: (2022)

Comparative Risk of Myocarditis/Pericarditis Following Second Doses of BNT162b2 and mRNA-1273 Coronavirus Vaccines
por: Naveed, Zaeema, et al.
Publicado: (2022)

mRNA Vaccination Decreases COVID-19-Associated Morbidity and Mortality Among Organ Transplant Recipients: A Contemporary Cohort Study
por: Lerner, Alexis Hope, et al.
Publicado: (2022)

Efficacy of Messenger RNA–1273 Against Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition in Young Adults From March to December 2021
por: Stephenson, Kathryn E, et al.
Publicado: (2023)

Incidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine (Moderna) in a Cohort of Hospital Employees
por: Jacobson, Mark A, et al.
Publicado: (2021)

Paucisymptomatic COVID-19 in lung transplant recipient following two doses of mRNA-1273 (Moderna) vaccine
por: Marinelli, Tina, et al.
Publicado: (2021)

mrna-1273: Erythema nodosum: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dib4dim3u04b6f17gl5o5ti6jq